Predict your next investment

Corporation
FINANCIAL | Asset/Financial Management
driehaus.com

See what CB Insights has to offer

Stage

Unattributed - VIII | Alive

Total Raised

$8.7M

Last Raised

$890K | 5 yrs ago

About Driehaus Capital Management

Driehaus Capital Management is a privately-held, independent investment adviser managing global, emerging markets, and U.S. growth equity, hedged equity, and absolute return investment strategies. The firm serves a diverse institutional client base comprised of corporate and public pensions, endowments, foundations, sub-advisory, financial advisors and family offices, globally. Driehaus' niche is that of a smaller, performance-oriented investment adviser with the resources of a much larger organization.

Driehaus Capital Management Headquarter Location

25 East Erie Street

Chicago, Illinois, 60611,

United States

312-587-3800

Latest Driehaus Capital Management News

DiCE Molecules Raises $60M in Series C-1 Financing

Aug 24, 2021

DiCE Molecules, a San Francisco, CA-based biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, completed its $60m Series C-1 financing.The round was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital, as well as existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management.DiCE Molecules is a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.The company’s platform is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs) as effectively as systemic biologics.The company is also developing oral therapeutic candidates targeting α4ß7 integrin and αVß1/αVß6 integrin for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Driehaus Capital Management Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Driehaus Capital Management Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.